<p>波士顿，2026 年 1 月 8 日（GLOBE NEWSWIRE）——Monte Rosa Therapeutics, Inc.（“Monte Rosa”）（纳斯达克：GLUE），一家开发新型分子胶降解剂（MGD）药物的临床阶段生物技术公司，今天宣布以每股 24.00 美元的公开发行价格，定价 11,125,000 股普通股的承销公开发行，并向某些投资者提供预融资认股权证，以每个预融资认股权证 23.9999 美元的公开发行价格购买 1,375,000 股普通股，这代表每股普通股的公开发行价格减去每个预融资认股权证的 0.0001 美元行使价格。Monte Rosa 还授予承销商一个 30 天的选择权，以公开发行价格购买最多 1,875,000 股普通股，扣除承销折扣和佣金。Monte Rosa 预计此次发行的毛收益约为 3 亿美元，未扣除承销折扣和佣金及发行费用，不包括承销商购买额外股份的选择权行使。所有发行的股份和预融资认股权证均由 Monte Rosa 出售。此次发行预计将在 2026 年 1 月 12 日左右完成，具体取决于满足惯例的交割条件。</p>
<p>Jefferies、TD Cowen 和 Piper Sandler 担任此次发行的联合账簿管理人。Wedbush PacGrow 和 LifeSci Capital 担任此次发行的被动账簿管理人。</p>
<p>这些股份和预融资认股权证由 Monte Rosa 根据之前于 2025 年 3 月 20 日向美国证券交易委员会（SEC）提交并于 2025 年 3 月 31 日获得 SEC 批准的有效货架注册声明进行发行（文件编号：333-285942）。此次发行仅通过书面招股说明书和招股说明书补充进行，这些文件构成注册声明的一部分。与此次发行相关并描述其条款的初步招股说明书补充已向 SEC 提交，并可在 SEC 网站 www.sec.gov 上获取。</p>
<p>与此次发行相关并描述最终条款的最终招股说明书补充将在 SEC 提交，并可在可用时从 Jefferies LLC 获取，注意：股权承销招股说明书部门，地址：520 Madison Avenue, 2nd Floor, New York, New York 10022，电话：(877) 821-7388，或通过电子邮件联系 Prospectus_Department@Jefferies.com，TD Securities (USA) LLC，地址：c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717，电子邮件：TDManualrequest@broadridge.com，Piper Sandler &amp; Co.，地址：350 North 5th Street, Suite 1000, Minneapolis, MN 55401，注意：招股说明书部门，电话：(800) 747-3924，或通过电子邮件联系 prospectus@psc.com，Wedbush Securities Inc.，注意：ECM 部门，地址：600 Montgomery Street, 29th Floor, San Francisco, CA 94111，或通过电子邮件联系 ecm@wedbush.com，或 LifeSci Capital LLC，地址：1700 Broadway, 40th Floor, New York, New York 10019，或通过电子邮件联系 compliance@lifescicapital.com。</p>
<p>本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何州或司法管辖区内进行这些证券的出售，除非在任何此类州或司法管辖区的证券法下进行注册或资格认证。</p>
<p><strong>关于 Monte Rosa</strong></p>
<p>Monte Rosa Therapeutics 是一家临床阶段的生物技术公司，开发高度选择性的分子胶降解剂（MGD）药物，旨在为患有严重疾病的患者提供治疗。MGD 是小分子蛋白降解剂，具有治疗许多其他治疗方式（包括其他降解剂）无法治疗的疾病的潜力。Monte Rosa 的 QuEEN™（定量和工程化的新底物消除）发现引擎结合了人工智能指导的化学、多样的化学库、结构生物学和蛋白质组学，以合理设计具有前所未有选择性的 MGD。Monte Rosa 开发了行业领先的首创和唯一 MGD 管线，涵盖自身免疫和炎症疾病、肿瘤学等领域，目前有三个项目在临床阶段。Monte Rosa 与领先的制药公司在免疫学、肿瘤学和神经学领域开展持续合作。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含明确和隐含的 “前瞻性声明”，包括根据 1995 年《私人证券诉讼改革法》及其修订版的前瞻性声明，包括但不限于关于 Monte Rosa 对公开发行的时间和完成的预期的隐含和明确声明，包括与发行相关的惯例交割条件的满足。前瞻性声明包括所有非历史事实的声明，在某些情况下，可以通过诸如 “可能”、“或许”、“将”、“可以”、“会”、“应该”、“期望”、“打算”、“计划”、“目标”、“预期”、“相信”、“估计”、“预测”、“潜在”、“继续”、“正在进行” 或这些术语的否定形式，或其他类似术语来识别关于未来的声明。</p>
<p>本新闻稿中的任何前瞻性声明均基于管理层当前的预期和信念，并受到多种风险、不确定性和重要因素的影响，这些因素可能导致实际事件或结果与本新闻稿中所表达或暗示的任何前瞻性声明存在重大差异，包括但不限于与市场条件相关的不确定性以及与公开发行相关的惯常成交条件的满足。这些风险和不确定性在 Monte Rosa 最近的 10-K 表格年度报告中的 “风险因素” 部分以及最近的 10-Q 表格季度报告和任何后续向 SEC 提交的文件中有更详细的描述。此外，任何前瞻性声明仅代表 Monte Rosa 截至本日期的观点，不应被视为其在任何后续日期的观点。Monte Rosa 明确声明不承担根据适用法律更新任何前瞻性声明的义务。对于任何此类前瞻性声明的准确性，不作任何明示或暗示的陈述或保证。</p>
<p><strong>投资者</strong></p>
<p>Andrew Funderburk</p>
<p>ir@monterosatx.com</p>
<p><strong>媒体</strong></p>
<p>Cory Tromblee, Scient PR</p>
<p>media@monterosatx.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU1qYzJNQ00zTXpVeU56WTVJekl5TURrMU5EVT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU1qYzJNQ00zTXpVeU56WTVJekl5TURrMU5EVT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Njc5Y2VlN2ItYTkzNC00NGQ4LWE5MWItMDEyOTU4YTljNDM4LTEyMjEwOTgtMjAyNi0wMS0wOS1lbg==/tiny/Monte-Rosa-Therapeutics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Njc5Y2VlN2ItYTkzNC00NGQ4LWE5MWItMDEyOTU4YTljNDM4LTEyMjEwOTgtMjAyNi0wMS0wOS1lbg==/tiny/Monte-Rosa-Therapeutics-Inc-.png"/></p>

GLUE

<p>Monte Rosa Therapeutics, Inc. 宣布了一项 3 亿美元的承销公开发行定价，包括 11,125,000 股普通股，每股定价为 24.00 美元，以及 1,375,000 股预付认股权证，每股定价为 23.9999 美元。该发行预计将于 2026 年 1 月 12 日完成，需满足惯例条件。Jefferies、TD Cowen 和 Piper Sandler 是联合账簿管理人。该发行是在与美国证券交易委员会（SEC）有效的货架注册声明下进行的。Monte Rosa 专注于开发用于治疗严重疾病的分子胶水降解药物</p>

<p>BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwritten public offering of 11,125,000 shares of its common stock at a public offering price of $24.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,375,000 shares of common stock at a public offering price of $23.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. Monte Rosa also granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Monte Rosa from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $300 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares and pre-funded warrants in the offering are to be sold by Monte Rosa. The offering is expected to close on or about January 12, 2026, subject to satisfaction of customary closing conditions.</p>
<div class="lb-trans"><p>波士顿，2026 年 1 月 8 日（GLOBE NEWSWIRE）——Monte Rosa Therapeutics, Inc.（“Monte Rosa”）（纳斯达克：GLUE），一家开发新型分子胶降解剂（MGD）药物的临床阶段生物技术公司，今天宣布以每股 24.00 美元的公开发行价格，定价 11,125,000 股普通股的承销公开发行，并向某些投资者提供预融资认股权证，以每个预融资认股权证 23.9999 美元的公开发行价格购买 1,375,000 股普通股，这代表每股普通股的公开发行价格减去每个预融资认股权证的 0.0001 美元行使价格。Monte Rosa 还授予承销商一个 30 天的选择权，以公开发行价格购买最多 1,875,000 股普通股，扣除承销折扣和佣金。Monte Rosa 预计此次发行的毛收益约为 3 亿美元，未扣除承销折扣和佣金及发行费用，不包括承销商购买额外股份的选择权行使。所有发行的股份和预融资认股权证均由 Monte Rosa 出售。此次发行预计将在 2026 年 1 月 12 日左右完成，具体取决于满足惯例的交割条件。</p>
</div><p>Jefferies, TD Cowen and Piper Sandler are acting as joint book-running managers for the offering. Wedbush PacGrow and LifeSci Capital are acting as passive bookrunners for the offering.</p>
<div class="lb-trans"><p>Jefferies、TD Cowen 和 Piper Sandler 担任此次发行的联合账簿管理人。Wedbush PacGrow 和 LifeSci Capital 担任此次发行的被动账簿管理人。</p>
</div><p>The shares and pre-funded warrants are being offered by Monte Rosa pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC) on March 20, 2025 and declared effective by the SEC on March 31, 2025 (File No. 333-285942). The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov.</p>
<div class="lb-trans"><p>这些股份和预融资认股权证由 Monte Rosa 根据之前于 2025 年 3 月 20 日向美国证券交易委员会（SEC）提交并于 2025 年 3 月 31 日获得 SEC 批准的有效货架注册声明进行发行（文件编号：333-285942）。此次发行仅通过书面招股说明书和招股说明书补充进行，这些文件构成注册声明的一部分。与此次发行相关并描述其条款的初步招股说明书补充已向 SEC 提交，并可在 SEC 网站 www.sec.gov 上获取。</p>
</div><p>The final prospectus supplement relating to and describing the final terms of the offering will be filed with the SEC and may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com, TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, email at TDManualrequest@broadridge.com, Piper Sandler &amp; Co., 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com, Wedbush Securities Inc., Attn: ECM Department, 600 Montgomery Street, 29th Floor, San Francisco, CA 94111 or via email at ecm@wedbush.com or LifeSci Capital LLC at 1700 Broadway, 40th Floor, New York, New York 10019, or by email at compliance@lifescicapital.com.</p>
<div class="lb-trans"><p>与此次发行相关并描述最终条款的最终招股说明书补充将在 SEC 提交，并可在可用时从 Jefferies LLC 获取，注意：股权承销招股说明书部门，地址：520 Madison Avenue, 2nd Floor, New York, New York 10022，电话：(877) 821-7388，或通过电子邮件联系 Prospectus_Department@Jefferies.com，TD Securities (USA) LLC，地址：c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717，电子邮件：TDManualrequest@broadridge.com，Piper Sandler &amp; Co.，地址：350 North 5th Street, Suite 1000, Minneapolis, MN 55401，注意：招股说明书部门，电话：(800) 747-3924，或通过电子邮件联系 prospectus@psc.com，Wedbush Securities Inc.，注意：ECM 部门，地址：600 Montgomery Street, 29th Floor, San Francisco, CA 94111，或通过电子邮件联系 ecm@wedbush.com，或 LifeSci Capital LLC，地址：1700 Broadway, 40th Floor, New York, New York 10019，或通过电子邮件联系 compliance@lifescicapital.com。</p>
</div><p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何州或司法管辖区内进行这些证券的出售，除非在任何此类州或司法管辖区的证券法下进行注册或资格认证。</p>
</div><p><strong>About Monte Rosa</strong></p>
<div class="lb-trans"><p><strong>关于 Monte Rosa</strong></p>
</div><p>Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology and neurology.</p>
<div class="lb-trans"><p>Monte Rosa Therapeutics 是一家临床阶段的生物技术公司，开发高度选择性的分子胶降解剂（MGD）药物，旨在为患有严重疾病的患者提供治疗。MGD 是小分子蛋白降解剂，具有治疗许多其他治疗方式（包括其他降解剂）无法治疗的疾病的潜力。Monte Rosa 的 QuEEN™（定量和工程化的新底物消除）发现引擎结合了人工智能指导的化学、多样的化学库、结构生物学和蛋白质组学，以合理设计具有前所未有选择性的 MGD。Monte Rosa 开发了行业领先的首创和唯一 MGD 管线，涵盖自身免疫和炎症疾病、肿瘤学等领域，目前有三个项目在临床阶段。Monte Rosa 与领先的制药公司在免疫学、肿瘤学和神经学领域开展持续合作。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Monte Rosa’s expectations regarding the timing and closing of the public offering, including the satisfaction of customary closing conditions related to the offering. Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future.</p>
<div class="lb-trans"><p>本新闻稿包含明确和隐含的 “前瞻性声明”，包括根据 1995 年《私人证券诉讼改革法》及其修订版的前瞻性声明，包括但不限于关于 Monte Rosa 对公开发行的时间和完成的预期的隐含和明确声明，包括与发行相关的惯例交割条件的满足。前瞻性声明包括所有非历史事实的声明，在某些情况下，可以通过诸如 “可能”、“或许”、“将”、“可以”、“会”、“应该”、“期望”、“打算”、“计划”、“目标”、“预期”、“相信”、“估计”、“预测”、“潜在”、“继续”、“正在进行” 或这些术语的否定形式，或其他类似术语来识别关于未来的声明。</p>
</div><p>Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward- looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. These and the risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Monte Rosa’s most recent Annual Report on Form 10-K, as well as the most recent Quarterly Reports on Form 10-Q and any subsequent filings with the SEC. In addition, any forward-looking statements represent Monte Rosa’s views only as of as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Monte Rosa explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.</p>
<div class="lb-trans"><p>本新闻稿中的任何前瞻性声明均基于管理层当前的预期和信念，并受到多种风险、不确定性和重要因素的影响，这些因素可能导致实际事件或结果与本新闻稿中所表达或暗示的任何前瞻性声明存在重大差异，包括但不限于与市场条件相关的不确定性以及与公开发行相关的惯常成交条件的满足。这些风险和不确定性在 Monte Rosa 最近的 10-K 表格年度报告中的 “风险因素” 部分以及最近的 10-Q 表格季度报告和任何后续向 SEC 提交的文件中有更详细的描述。此外，任何前瞻性声明仅代表 Monte Rosa 截至本日期的观点，不应被视为其在任何后续日期的观点。Monte Rosa 明确声明不承担根据适用法律更新任何前瞻性声明的义务。对于任何此类前瞻性声明的准确性，不作任何明示或暗示的陈述或保证。</p>
</div><p><strong>Investors</strong></p>
<div class="lb-trans"><p><strong>投资者</strong></p>
</div><p>Andrew Funderburk</p>
<div class="lb-trans"><p>Andrew Funderburk</p>
</div><p>ir@monterosatx.com</p>
<div class="lb-trans"><p>ir@monterosatx.com</p>
</div><p><strong>Media</strong></p>
<div class="lb-trans"><p><strong>媒体</strong></p>
</div><p>Cory Tromblee, Scient PR</p>
<div class="lb-trans"><p>Cory Tromblee, Scient PR</p>
</div><p>media@monterosatx.com</p>
<div class="lb-trans"><p>media@monterosatx.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU1qYzJNQ00zTXpVeU56WTVJekl5TURrMU5EVT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYyMjc2MCM3MzUyNzY5IzIyMDk1NDU="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Njc5Y2VlN2ItYTkzNC00NGQ4LWE5MWItMDEyOTU4YTljNDM4LTEyMjEwOTgtMjAyNi0wMS0wOS1lbg==/tiny/Monte-Rosa-Therapeutics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/Njc5Y2VlN2ItYTkzNC00NGQ4LWE5MWItMDEyOTU4YTljNDM4LTEyMjEwOTgtMjAyNi0wMS0wOS1lbg==/tiny/Monte-Rosa-Therapeutics-Inc-.png"/></p>

Monte Rosa Therapeutics 宣布 3 亿美元承销公开发行的定价 | GLUE 股票新闻